A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)
暂无分享,去创建一个
C. Wetmore | J. Reid | A. Scheck | C. Minard | B. Weigel | E. Fox | T. Cash | Xiaowei Liu